Arteriovenous Malformations Market

Market Overview:

The 7 major arteriovenous malformations markets are expected to exhibit a CAGR of 6.1% during 2024-2034.

The arteriovenous malformations market has been comprehensively analyzed in IMARC's new report titled "Arteriovenous Malformations Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Arteriovenous malformations are irregular tangles of blood vessels that directly connect arteries to veins, bypassing the capillary network. This congenital vascular disorder can occur in various parts of the body, including the brain and spinal cord. Arteriovenous malformations are mainly characterized by their potential to disrupt normal blood flow and oxygen exchange, leading to several health complications. The symptoms of the illness can vary widely depending on their location and size. Common neurological signs may include headaches, seizures, weakness, numbness, and even paralysis. In cases where an arteriovenous malformation ruptures, it can cause severe bleeding in the brain, leading to indications, such as sudden and severe headaches, neurological deficits, and loss of consciousness, which can be life-threatening. Diagnosing this ailment often involves a combination of imaging techniques like angiography, MRI (magnetic resonance imaging), and CT (computed tomography) scans. Angiography is particularly useful as it provides detailed visualizations of the abnormal blood vessels' structure and blood flow patterns.

The increasing incidences of numerous associated risk factors, including genetic predisposition, exposure to certain toxins or chemicals, abnormal embryonic development, hormonal changes, trauma, injury, etc., are primarily driving the arteriovenous malformations market. In addition to this, the inflating utilization of minimally invasive procedures, such as endovascular embolization, which involves blocking abnormal blood vessels to restore normal blood flow patterns, is also creating a positive outlook for the market. Moreover, the widespread adoption of physical and neurorehabilitation therapies, since they help in enhancing motor functions, coordination, and overall quality of life for individuals suffering from arteriovenous malformations, is further bolstering the market growth. Apart from this, the rising usage of gene therapy, that involves introducing functional genetic material to rectify or replace mutated genes responsible for the condition, is acting as another significant growth-inducing factor. Additionally, the emerging popularity of efficacious treatments, such as embolization, surgical resection, stereotactic radiosurgery, and pharmacological therapies aimed at managing symptoms and preventing adverse outcomes is also augmenting the market growth. Furthermore, the escalating application of targeted therapies, like anti-angiogenic drugs that work by inhibiting the generation of new blood vessels in the affected area, is expected to drive the arteriovenous malformations market during the forecast period.

IMARC Group's new report provides an exhaustive analysis of the arteriovenous malformations market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for arteriovenous malformations and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the arteriovenous malformations market in any manner.

Time Period of the Study

• Base Year: 2023
• Historical Period: 2018-2023
• Market Forecast: 2024-2034
   

Countries Covered

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan
   

Analysis Covered Across Each Country

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the arteriovenous malformations market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the arteriovenous malformations market
• Reimbursement scenario in the market
• In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current arteriovenous malformations marketed drugs and late-stage pipeline drugs.

In-Market Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

Late-Stage Pipeline Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report

Market Insights

• How has the arteriovenous malformations market performed so far and how will it perform in the coming years?
• What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
• What was the country-wise size of the arteriovenous malformations market across the seven major markets in 2023 and what will it look like in 2034?
• What is the growth rate of the arteriovenous malformations market across the seven major markets and what will be the expected growth over the next ten years?
• What are the key unmet needs in the market?
   

Epidemiology Insights

• What is the number of prevalent cases (2018-2034) of arteriovenous malformations across the seven major markets?
• What is the number of prevalent cases (2018-2034) of arteriovenous malformations by age across the seven major markets?
• What is the number of prevalent cases (2018-2034) of arteriovenous malformations by gender across the seven major markets?
• How many patients are diagnosed (2018-2034) with arteriovenous malformations across the seven major markets?
• What is the size of the arteriovenous malformations patient pool (2018-2023) across the seven major markets?
• What would be the forecasted patient pool (2024-2034) across the seven major markets?
• What are the key factors driving the epidemiological trend of arteriovenous malformations?
• What will be the growth rate of patients across the seven major markets?
   

Arteriovenous Malformations: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

• What are the current marketed drugs and what are their market performance?
• What are the key pipeline drugs and how are they expected to perform in the coming years?
• How safe are the current marketed drugs and what are their efficacies?
• How safe are the late-stage pipeline drugs and what are their efficacies?
• What are the current treatment guidelines for arteriovenous malformations drugs across the seven major markets?
• Who are the key companies in the market and what are their market shares?
• What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the arteriovenous malformations market?
• What are the key regulatory events related to the arteriovenous malformations market?
• What is the structure of clinical trial landscape by status related to the arteriovenous malformations market?
• What is the structure of clinical trial landscape by phase related to the arteriovenous malformations market?
• What is the structure of clinical trial landscape by route of administration related to the arteriovenous malformations market?